Stryker to Release Q2 2026 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- Financial Performance Growth: In Q1 2026, Stryker's net sales increased by 2.6% year-over-year to $6.02 billion, primarily driven by strong performance in the MedSurg and Neurotechnology segments, which generated $3.21 billion, while Orthopaedics contributed $2.81 billion, indicating the company's sustained growth potential in the medical technology sector.
- Profitability Improvement: The net earnings for Q1 rose by 13.9% to $0.74 billion, translating to $1.93 per share, compared to $0.65 billion and $1.69 per share in the previous year, reflecting effective strategies in cost control and market demand management.
- Future Outlook: Stryker anticipates organic net sales growth of 8.0% to 9.5% for the full year 2026, with adjusted earnings per diluted share expected to range between $14.90 and $15.10, demonstrating the company's confidence in future market performance and proactive growth strategies.
- Historical Performance Review: In Q2 2025, Stryker's consolidated net sales increased by 11.1% year-over-year to $6.022 billion, with MedSurg and Neurotechnology sales rising by 17.3%, showcasing the company's strong competitive position in the medical device market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYK
Wall Street analysts forecast SYK stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 329.740
Low
390.00
Averages
430.32
High
465.00
Current: 329.740
Low
390.00
Averages
430.32
High
465.00
About SYK
Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UBS Recommends Low Volatility Stocks to Stabilize Portfolios
- Strong Market Performance: The S&P 500 index rose 9.6% in the first half of 2026, achieving nearly a 15% increase in the second quarter, marking its best quarterly performance since 2020, despite investors facing turbulence including the onset of the Iran war.
- Low Volatility Stock Recommendations: UBS highlights the lagging performance of low volatility stocks as capital has concentrated in AI-driven sectors, suggesting investors focus on high-quality companies with resilient fundamentals and attractive valuations to mitigate portfolio swings.
- Positive Outlook for Yum Brands: The parent company of Taco Bell and KFC, Yum Brands, is expected to achieve its highest cash flow return on investment by 2027, with plans for international expansion and a KFC loyalty program driving topline growth, and its stock has risen over 10% this year.
- Significant Potential for Lockheed Martin: While UBS maintains a neutral stance on Lockheed Martin, it anticipates a positive reaction to its upcoming second-quarter earnings report, with a $35 billion defense contract potentially boosting 2026 performance, and the stock has increased by about 10%.
See More
Stryker to Release Q2 2026 Financial Results
- Financial Performance Growth: In Q1 2026, Stryker's net sales increased by 2.6% year-over-year to $6.02 billion, primarily driven by strong performance in the MedSurg and Neurotechnology segments, which generated $3.21 billion, while Orthopaedics contributed $2.81 billion, indicating the company's sustained growth potential in the medical technology sector.
- Profitability Improvement: The net earnings for Q1 rose by 13.9% to $0.74 billion, translating to $1.93 per share, compared to $0.65 billion and $1.69 per share in the previous year, reflecting effective strategies in cost control and market demand management.
- Future Outlook: Stryker anticipates organic net sales growth of 8.0% to 9.5% for the full year 2026, with adjusted earnings per diluted share expected to range between $14.90 and $15.10, demonstrating the company's confidence in future market performance and proactive growth strategies.
- Historical Performance Review: In Q2 2025, Stryker's consolidated net sales increased by 11.1% year-over-year to $6.022 billion, with MedSurg and Neurotechnology sales rising by 17.3%, showcasing the company's strong competitive position in the medical device market.
See More
Stryker Shares Surge 5.3% on Analyst Upgrade and Growth Prospects
- Significant Price Surge: Stryker (SYK) shares rose 5.3% in the last trading session to close at $332.71, with trading volume significantly exceeding normal levels, reflecting renewed investor optimism regarding the company's long-term growth prospects.
- Analyst Upgrade: A recent upgrade to 'Outperform' by analysts has bolstered investor confidence, alongside management's reaffirmation of full-year guidance, indicating a recovery from temporary cyber disruptions.
- Strong Earnings Expectations: Stryker is expected to report quarterly earnings of $3.49 per share, representing an 11.5% year-over-year increase, with revenues projected at $6.56 billion, up 8.9%, highlighting the company's robust performance in the medical device sector.
- Earnings Estimate Revision: Although the consensus EPS estimate has been slightly revised lower, the correlation between earnings estimate trends and stock price movements suggests that investors should monitor SYK's future performance to determine if this price increase can be sustained.
See More
Stryker Partners with Golfer Shane Lowry to Promote Joint Replacement Awareness
- Brand Ambassador Partnership: Stryker has announced a partnership with globally recognized golfer Shane Lowry, naming him a brand ambassador for its Joint Replacement division, leveraging Lowry's personal experiences to raise awareness about joint pain and the role of caregivers.
- Personal Story Sharing: As a caregiver to his father, Lowry has witnessed the impact of joint pain on patients and families, and by sharing his story, he aims to encourage more caregivers to actively engage in their loved ones' treatment and recovery processes.
- Global Awareness Campaign: This collaboration will utilize media, social channels, and educational initiatives to elevate the importance of caregivers in the joint replacement journey, helping them better understand treatment options and recovery processes.
- Patient Impact: Katherine Truppi, president of Stryker's Joint Replacement division, emphasized that joint replacement is more than surgery; it is a personal journey affecting both patients and their supporters, and Lowry's story authentically conveys this perspective to help more people seek support.
See More
IYH ETF 52-Week Price Range Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
See More
Jim Cramer's Insights on Multiple Stocks
- Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
- Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
- Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
- Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
See More
UBS Recommends Low Volatility Stocks to Stabilize Portfolios
- Strong Market Performance: The S&P 500 index rose 9.6% in the first half of 2026, achieving nearly a 15% increase in the second quarter, marking its best quarterly performance since 2020, despite investors facing turbulence including the onset of the Iran war.
- Low Volatility Stock Recommendations: UBS highlights the lagging performance of low volatility stocks as capital has concentrated in AI-driven sectors, suggesting investors focus on high-quality companies with resilient fundamentals and attractive valuations to mitigate portfolio swings.
- Positive Outlook for Yum Brands: The parent company of Taco Bell and KFC, Yum Brands, is expected to achieve its highest cash flow return on investment by 2027, with plans for international expansion and a KFC loyalty program driving topline growth, and its stock has risen over 10% this year.
- Significant Potential for Lockheed Martin: While UBS maintains a neutral stance on Lockheed Martin, it anticipates a positive reaction to its upcoming second-quarter earnings report, with a $35 billion defense contract potentially boosting 2026 performance, and the stock has increased by about 10%.
See More
Stryker to Release Q2 2026 Financial Results
- Financial Performance Growth: In Q1 2026, Stryker's net sales increased by 2.6% year-over-year to $6.02 billion, primarily driven by strong performance in the MedSurg and Neurotechnology segments, which generated $3.21 billion, while Orthopaedics contributed $2.81 billion, indicating the company's sustained growth potential in the medical technology sector.
- Profitability Improvement: The net earnings for Q1 rose by 13.9% to $0.74 billion, translating to $1.93 per share, compared to $0.65 billion and $1.69 per share in the previous year, reflecting effective strategies in cost control and market demand management.
- Future Outlook: Stryker anticipates organic net sales growth of 8.0% to 9.5% for the full year 2026, with adjusted earnings per diluted share expected to range between $14.90 and $15.10, demonstrating the company's confidence in future market performance and proactive growth strategies.
- Historical Performance Review: In Q2 2025, Stryker's consolidated net sales increased by 11.1% year-over-year to $6.022 billion, with MedSurg and Neurotechnology sales rising by 17.3%, showcasing the company's strong competitive position in the medical device market.
See More
Stryker Shares Surge 5.3% on Analyst Upgrade and Growth Prospects
- Significant Price Surge: Stryker (SYK) shares rose 5.3% in the last trading session to close at $332.71, with trading volume significantly exceeding normal levels, reflecting renewed investor optimism regarding the company's long-term growth prospects.
- Analyst Upgrade: A recent upgrade to 'Outperform' by analysts has bolstered investor confidence, alongside management's reaffirmation of full-year guidance, indicating a recovery from temporary cyber disruptions.
- Strong Earnings Expectations: Stryker is expected to report quarterly earnings of $3.49 per share, representing an 11.5% year-over-year increase, with revenues projected at $6.56 billion, up 8.9%, highlighting the company's robust performance in the medical device sector.
- Earnings Estimate Revision: Although the consensus EPS estimate has been slightly revised lower, the correlation between earnings estimate trends and stock price movements suggests that investors should monitor SYK's future performance to determine if this price increase can be sustained.
See More
Stryker Partners with Golfer Shane Lowry to Promote Joint Replacement Awareness
- Brand Ambassador Partnership: Stryker has announced a partnership with globally recognized golfer Shane Lowry, naming him a brand ambassador for its Joint Replacement division, leveraging Lowry's personal experiences to raise awareness about joint pain and the role of caregivers.
- Personal Story Sharing: As a caregiver to his father, Lowry has witnessed the impact of joint pain on patients and families, and by sharing his story, he aims to encourage more caregivers to actively engage in their loved ones' treatment and recovery processes.
- Global Awareness Campaign: This collaboration will utilize media, social channels, and educational initiatives to elevate the importance of caregivers in the joint replacement journey, helping them better understand treatment options and recovery processes.
- Patient Impact: Katherine Truppi, president of Stryker's Joint Replacement division, emphasized that joint replacement is more than surgery; it is a personal journey affecting both patients and their supporters, and Lowry's story authentically conveys this perspective to help more people seek support.
See More
IYH ETF 52-Week Price Range Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
See More
Jim Cramer's Insights on Multiple Stocks
- Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
- Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
- Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
- Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
See More
